Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: From medical needs to a new treatment algorithm

European Journal of Dermatology

Volumn 23, Issue 6, 2013, Pages 758-766

  Luger, Thomas ^a   De Raeve, Linda ^b   Gelmetti, Carlo ^c   Kakourou, Talia ^d   Katsarou, Alexandra ^d   Lambert, Julien ^e   Morren, Marie Anne ^f   Oranje, Arnold ^g   Ruer, Mireille ^h   Serdaroglu, Server ⁱ   Torrelo, Antonio ^j   Werfel, Thomas ^k  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF ATHENS   (Greece)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^h Erasmus MC Sophia Children's Hospital ^*  (France)

ⁱ ISTANBUL UNIVERSITY   (Turkey)

^j HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Atopic dermatitis; Pimecrolimus; Topical calcineurin inhibitor; Topical corticosteroid; Treatment algorithm

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; EMOLLIENT AGENT; FILAGGRIN; INVOLUCRIN; LORICRIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PIMECROLIMUS; PROLINE RICH PROTEIN; SUBSTANCE P; TACROLIMUS; TRIAMCINOLONE ACETONIDE; VANILLOID RECEPTOR 1; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; SKIN CREAM;

ALGORITHM; ATOPIC DERMATITIS; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; EPIDERMIS; HUMAN; NONHUMAN; PRURITUS; QUALITY OF LIFE; REVIEW; SAFETY; SKIN ATROPHY; SKIN INFECTION; ANALOGS AND DERIVATIVES; ATROPHY; CHEMICALLY INDUCED; DERMATITIS, ATOPIC; MEDICATION COMPLIANCE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN;

ADRENAL CORTEX HORMONES; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATROPHY; DERMATITIS, ATOPIC; HUMANS; MEDICATION ADHERENCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; SKIN CREAM; TACROLIMUS;

EID: 84893217641     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2169     Document Type: Review

References (95)

1. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152-69.
2. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317-28.
3. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-60.
4. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483-94.
5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124: 1251-8.
6. McKenna SP, Doward LC. Quality of life of children with atopic dermatitis and their families. Curr Opin Allergy Clin Immunol 2008; 8: 228-31.
7. Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol 2011; 7 Suppl 1: S4.
8. Barnetson RS, Rogers M. Childhood atopic eczema. BMJ 2002; 324: 1376-9.
9. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012; 22: 850-9.
10. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010; 125: 4-13.
11. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am 2010; 30: 269-80.
12. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105: 99-106.
13. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-8.
14. Plotz SG, Ring J. What's new in atopic eczema? Expert Opin Emerg Drugs 2010; 15: 249-67.
15. Cork MJ, Danby S. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nurs 2009; 18: 872-7.
16. Kalavala M, Dohil MA. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. Am J Clin Dermatol 2011; 12: 15-24.
17. Hultsch T, Müller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998; 290: 501-7.
18. Grassberger M, Baumruker T, Enz A, et al. A novel antiinflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73.
19. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26: 1176-93.
20. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-32.
21. Hoare C, LiWan PA, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
22. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004; 50: 391-404.
23. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Junger M, Bräutigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-7.
24. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
25. Sigurgeirsson B, Ho V, Ferrandiz C, Andriano K, Grinienko A, Jimenez P. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 1290-301.
26. Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008; 158: 1083-93.
27. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-28.
28. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.
29. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol 2009; 20: 59-66.
30. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-37.
31. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801-7.
32. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140: 1114-21.
33. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol 2009; 26: 551-8.
34. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-60.
35. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
36. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006; 61: 375-81.
37. Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis 2007; 79: 65-72.
38. Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006; 7: 121-31.
39. Luger TA, Gollnick H, Schwennesen T, Bextermöller R, Freytag S, Bräutigam M. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis. J Dtsch Dermatol Ges 2007; 5: 908-14.
40. Sunderkötter C, Weiss JM, Bextermöller R, Loffler H, Schneider D. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006; 4: 301-6.
41. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-25.
42. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60: 984-92.
43. Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol 2011; 25: 12-8.
44. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 691-3.
45. Whalley D, Huels J, McKenna SP, Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002; 110: 1133-6.
46. Staab D, Kaufmann R, Bräutigam M, Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005; 16: 527-33.
47. McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006; 20: 248-54.
48. Ingram JR, Martin JA, Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2009; 10: 229-37.
49. Gollnick H, Luger T, Freytag S, Bräutigam M. StabiEL: stabilization of skin condition with Elidel-a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol 2008; 22: 1319-25.
50. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996; 37 Suppl 1: S10-3.
51. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165: 808-14.
52. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6.
53. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000; 201: 242-5.
54. Nuutinen P, Riekki R, Parikka M, et al. Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol 2003; 148: 39-45.
55. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus-an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-30.
56. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13.
57. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007; 157: 954-9.
58. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 124: R19-28.
59. Grzanka A, Zebracka-Gala J, Rachowska R, Bozek A, Kowalska M, Jarzab J. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol 2012; 21: 184-8.
60. Jensen JM, Scherer A, Wanke C, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012; 67: 413-23.
61. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin 2008; 24: 985-94.
62. Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol 2009; 160: 415-22.
63. Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. J Eur Acad Dermatol Venereol 2008; 22: 195-203.
64. Zuberbier T, Bräutigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008; 22: 718-21.
65. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003; 4: 641-54.
66. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667-74.
67. Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr 2003; 15: 399-404.
68. Wong VK, Della CC, Schonfeld S, Mastrangelo AM, Lebwohl M. Use and abuse of topical corticosteroids in infections of the skin and related structures. J Drugs Dermatol 2003; 2: 268-76.
69. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-84.
70. Jensen JM, Ahrens K, Meingassner J, et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp Dermatol 2011; 20: 783-8.
71. Büchau AS, Schauber J, Hultsch T, Stuetz A, Gallo RL. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008; 128: 2646-54.
72. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15: 169-78.
73. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
74. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211: 174-87.
75. Langley RG, Luger TA, Cork MJ, Schneider D, Paul C. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007; 215 Suppl 1: 27-44.
76. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a metaanalysis of randomized clinical trials. J Dermatolog Treat 2010; 21: 144-56.
77. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861-73.
78. Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol 2010; 163: 70-7.
79. Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007; 156: 1020-6.
80. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5: e10968.
81. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35.
82. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981 in patients with atopic dermatitis. Dermatology 2002; 204: 63-8.
83. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969-73.
84. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. Exp Dermatol 2006; 15: 138-41.
85. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602-9.
86. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52-6.
87. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16.
88. Carr WW. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatr Drugs 2013.
89. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818-23.
90. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011; 165: 465-73.
91. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112: S118-27.
92. Bonifazi E, Garofalo L, Pisani V, Meneghini CL. Role of some infectious agents in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 98-100.
93. Giannetti A. Viral skin diseases in atopic dermatitis. In: Happle R, Grosshans E, editors. Pediatric dermatology. Berlin: Springer-Verlag, 1987: 110-3.
94. David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch Dis Child 1985; 60: 338-43.
95. Seize MB, Ianhez M, Cestari SC. A study of the correlation between molluscum contagiosum and atopic dermatitis in children. An Bras Dermatol 2011; 86: 663-8.